KGA-2727
KGA-2727 is a first selective, high-affinity and orally active SGLT1 inhibitor with Kis of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat) . KGA-2727 has antidiabetic efficacy[1].
Product Specifications
CAS Number
666842-36-0
UNSPSC
12352005
Hazard Statement
H302, H319
Target
SGLT
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/kga-2727.html
Purity
98.84
Solubility
DMSO : 200 mg/mL (ultrasonic) |Ethanol : 100 mg/mL (ultrasonic) |H2O : 20 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(N)CCNCCCOC1=CC=C(CC2=C(C(C)C)NN=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)C(C)=C1
Molecular Formula
C26H40N4O8
Molecular Weight
536.62
Precautions
H302, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
SGLT1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
KCNH1 Polyclonal Antibody, APC-Cy5.5 Conjugated
